A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Sponsor: Genentech, Inc.
Terminated
Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.
Other terminated trials from Genentech, Inc.
- Idiopathic Pulmonary Fibrosis · Phase PHASE2 · Jan 2026
- Non-small Cell Lung Cancer · Phase PHASE2 · Nov 2025
- Solid Tumour · Phase PHASE1 · Nov 2025
- Diffuse Large B-cell Lymphoma · Oct 2025
- Hepatocellular Carcinoma · Phase PHASE2 · Jun 2025
More terminations from Genentech, Inc.
Other Ulcerative Colitis trials with similar outcome
Listed as NCT06137183, this PHASE2 trial focuses on Ulcerative Colitis and remains terminated or withdrawn. Sponsored by Genentech, Inc., it has been updated 20 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Terminated PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
May 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
▶ Show 15 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
?ód?, Poland , Athens, Greece , Atlanta, United States , Belgrade, Serbia , Bologna, Italy , Brasília, Brazil , Brno, Czechia , Busan, South Korea , Bydgoszcz, Poland , Camarillo, United States and 51 more locations